⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174873 | 0.67 | — | — | |
| SCHEMBL18952815 | 0.67 | — | — | |
| SCHEMBL65195 | 0.64 | — | — | |
| SCHEMBL27769891 | 0.62 | — | — | |
| Pyrazine SCHEMBL28188517 | 0.59 | DYRK1A (0.41) | — | |
| SCHEMBL136008 | 0.59 | — | — | |
| SCHEMBL19153182 | 0.58 | GRM5 (0.37) | — | |
| SCHEMBL26373838 | 0.58 | PTGS1 (0.52) | — | |
| SCHEMBL3266033 | 0.58 | — | — | |
| SCHEMBL268000 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 864 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | claimed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | claimed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. | 2023-03-30 | — | — | US | claimed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-11524934-B2 | Phenylamine compounds | PI INDUSTRIES LTD (IN) | 2022-12-13 | — | — | US | claimed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| US-11382918-B2 | Methods for treating Huntington's Disease | PTC THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | claimed |
| EP-2828262-A1 | IMIDAZOTRIAZINONE COMPOUNDS | Forum Pharmaceuticals Inc. (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142269-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | WO | claimed |
| WO-2013010880-A1 | NEW CRTH2 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2013-01-24 | — | — | WO | claimed |
| EP-2548876-A1 | New CRTh2 antagonists | Almirall, S.A. (ES) | 2013-01-23 | — | — | EP | claimed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| US-20090043116-A1 | HETERO-POLYCYCLIC COMPOUNDS, AND COLORING MATTERS, PIGMENTS, DYES, COLOR-CHANGING MATERIAL COMPOSITIONS, AND COLOR-CHANGING FILMS, MADE BY USING THE COMPOUNDS | IDEMITSU KOSAN CO., LTD. (JP) | 2009-02-12 | — | — | US | claimed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | claimed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | claimed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |